Very conservative estimates make break-even a while off (not three years), but that does not account for off label use of Ryoncil, which will be substantial. It also doesn't account for COVID-related approvals.
The company will enter partnerships for CHF and CLBP indications that will secure sufficient money to cover the cost of upscaling manufacturing.
Do you really think the US Government (and other governments) are going to require the company to do a CR to manufacture for COVID patients?
If this COVID trial goes well, we could very well be making a profit by the end of the year.
MSB Trading - 2020, page-6453
-
- There are more pages in this discussion • 16,708 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.41 |
Change
-0.050(3.44%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.43 | $1.39 | $1.650M | 1.176M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 26716 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.41 | 5727 | 8 |
View Market Depth
| Last trade - 10.52am 16/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |